Literature DB >> 2852922

Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs.

M G Myers1, D I Bernstein, C J Harrison, L R Stanberry.   

Abstract

Treatment of previously infected guinea pigs with herpes simplex virus (HSV) glycoproteins reduces the frequency and severity of subsequent genital recurrences. An effective vaccine should also reduce episodes of viral shedding. In this study, HSV glycoproteins B and D treatment of animals experiencing recurrent genital herpes reduced the frequency of both clinical recurrences and cervicovaginal viral shedding. When virus was shed, however, the peak viral titer and duration of shedding was unaltered.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852922     DOI: 10.1016/0166-3542(88)90016-2

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  6 in total

1.  Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.

Authors:  Richard B Pyles; Debbie Higgins; Claudia Chalk; Anthony Zalar; Joseph Eiden; Carrie Brown; Gary Van Nest; Lawrence R Stanberry
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 2.  The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.

Authors:  Tiffany Kuo; Christine Wang; Tina Badakhshan; Sravya Chilukuri; Lbachir BenMohamed
Journal:  Vaccine       Date:  2014-10-16       Impact factor: 3.641

3.  A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Authors:  Ronald L Veselenak; Mark Shlapobersky; Richard B Pyles; Qun Wei; Sean M Sullivan; Nigel Bourne
Journal:  Vaccine       Date:  2012-10-04       Impact factor: 3.641

Review 4.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

5.  Successful application of prime and pull strategy for a therapeutic HSV vaccine.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Sita Awasthi; Peiwen Lu; Derek A Pullum; David A Dixon; Akiko Iwasaki; Harvey M Friedman
Journal:  NPJ Vaccines       Date:  2019-08-01       Impact factor: 7.344

6.  Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.

Authors:  V Durmanová; M Sapák; J Kosovský; I Rezuchová; M Kúdelová; M Buc; J Rajcáni
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.